 WESTLAKE VILLAGE, Calif. and NEW PROVIDENCE, N.J., Dec. 17, 2020 GLOBE NEWSWIRE -- MannKind Corporation Nasdaq: MNKD and Vertice Pharma today announced that they have entered into a co-promotion agreement for ThyquidityTM levothyroxine sodium oral solution through MannKinds specialty sales force. THYQUIDITY is indicated as a replacement therapy in primary thyroidal, secondary pituitary, and tertiary hypothalamic congenital or acquired hypothyroidism. THYQUIDITY is not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients or hypothyroidism during the recovery phase of subacute thyroiditis. 